Home | Log in | Register


Course Presenter

Roger Chou, MD, FACP

Target Audience

The target audience for this learning activity includes physicians, pharmacists, advanced practice registered nurses, physician assistants, registered nurses, health educators, case managers, and individuals involved in developing clinical programs or policies regarding HCV screening.

Program Description

Hepatitis C virus (HCV) infection is a leading cause of complications from chronic liver disease and was the underlying or contributing cause of 16,000 deaths in the United States in 2010. Current estimates are that approximately 3.2 million people in the United States have chronic HCV infection, although many are unaware that they carry the virus. Screening could identify patients at earlier stages of disease, when interventions might be effective in improving clinical outcomes or reducing transmission risk. The material in this learning module covers the results and conclusions from the comparative effectiveness review (CER) titled Screening for Hepatitis C Virus Infection in Adults, which was produced for the Agency for Healthcare Research and Quality (AHRQ) by the Pacific Northwest (formerly Oregon) Evidence-based Practice Center. The full report is a comprehensive systematic review of the existing body of evidence about benefits and harms of HCV screening in asymptomatic adults without known liver enzyme abnormalities. The relative effectiveness of various screening strategies for HCV infection, including effects on clinical outcomes, and the potential harms of screening are discussed. Evidence about the impact of counseling interventions on clinical and intermediate outcomes is presented and the effects of labor-and-delivery practices and breastfeeding on mother-to-child transmission of HCV infection are also discussed. This monograph will also briefly discuss the effectiveness of antiviral treatments on intermediate and clinical outcomes, and will mention some new antiviral therapies under investigation.

Overall Learning Purpose/Goal

At the conclusion of this activity, participants will be able to:

  1. Discuss key evidence regarding the clinical benefits and harms of screening for HCV infection in non-pregnant and pregnant asymptomatic adults.
  2. Apply the updated U.S. Preventive Services Task Force (USPSTF) recommendations for screening for HCV infection.
  3. Identify limitations in the current evidence regarding the clinical benefits and harms of screening for HCV infection in nonpregnant and pregnant asymptomatic adults.
  • For Pharmacists Only: Provide accurate and appropriate counsel as part of the treatment team.
  • For Registered Nurses Only: Provide appropriate care and counsel for patients and their families.

Credit Available

  • Case Managers – maximum of 1.0 clock hours
  • Certified Health Education Specialists – maximum of 1.0 contact hours
  • Nurse Practitioners – maximum of 1.0 contact hours
  • Registered Nurses – maximum of 1.0 contact hours
  • Pharmacists – maximum of 1.0 contact hours
  • Physicians – maximum of 1.0 AMA PRA Category 1 Credit(s)TM

Faculty & Credentials

Roger Chou, MD, FACP
Associate Professor of Medicine at Oregon Health & Science University and
Director of the Pacific Northwest Evidence-based Practice Center.

Dr. Chou is an Associate Professor in the Departments of Medicine and Medical Informatics & Clinical Epidemiology at Oregon Health & Science University (OHSU) School of Medicine and Staff Physician in the Internal Medicine Clinic at OHSU.  He is also the Director of the Pacific Northwest Evidence-based Practice Center, funded by the Agency for Healthcare Research and Quality (AHRQ), and an Investigator for the Scientific Resource Center of the AHRQ Effective Health Care Program.  He is a Fellow of the American College of Physicians, and served as a member of the American College of Physician's Clinical Guidelines Committee.  Dr. Chou has led a number of reviews on diagnostic screening tests for the U.S. Preventive Services Task Force, and other reviews in the areas of imaging and interventional diagnostic tests for low back pain, imaging for hepatocellular carcinoma, blood tests to diagnose fibrosis and cirrhosis, and others.

Disclosures

  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine and Hayes, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
  • The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Designated for 0.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
  • Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
  • Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
  • Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-14-151-H01-P)
  • Type of Activity: Application 
    • This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers.
    • This program is approved for 1.0 contact hour(s) of continuing education by the American Association of Nurse Practitioners. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
    • Sponsored by Hayes, Inc., a designated a provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced-level continuing education contact hours available are 1.0.

If you have questions about the presentation, please e-mail us at: Educationservices@hayesinc.com.

  • This educational activity has been funded by AHRQ.
  • There has been no outside commercial support for this activity.
  • Presenter(s) and planning committee members have no conflicts of interest, relevant financial relationships, or sponsorships to disclose.
  • Criteria for successful completion:
    • Each participant must complete an evaluation and must successfully pass the posttest with a grade of 75% or higher to obtain the CE credit.
    • For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks

Required Hardware/Software

AHRQ requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.